SCHEDULE: Soleus Entities Disclose 2.8% Passive Stake in Invivyd

Soleus Capital Management and affiliated entities report a combined 2.8% passive beneficial ownership in Invivyd, Inc. common stock.

Summary

• Soleus Capital Management, L.P., along with its affiliated entities Soleus Private Equity Fund III, L.P., Soleus Capital Master Fund, L.P., and related general partners and managers, collectively hold 7,708,727 shares of Invivyd, Inc. common stock.
• This represents a 2.8% beneficial ownership stake in Invivyd, Inc., calculated based on 277,064,852 shares outstanding.
• The shares are held for passive investment purposes, with no intent to change or influence control of the issuer.
• Soleus Private Equity Fund III, L.P. directly holds 1,680,160 shares, representing 0.6% of the class.
• Soleus Capital Master Fund, L.P. directly holds 6,028,567 shares, representing 2.2% of the class.
• Guy Levy, as the sole managing member of key Soleus entities, is deemed to beneficially own the aggregate 7,708,727 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure, typical for a passive beneficial ownership report. It provides transparency but does not inherently signal positive or negative operational developments for Invivyd, Inc.

Positives

• Increased institutional ownership by Soleus Capital Management and its affiliates may signal confidence in Invivyd, Inc.'s long-term prospects.

Negatives

• The reported ownership percentage of 2.8% is below the 5% threshold, indicating a relatively minor passive stake that may not significantly influence corporate governance or strategic direction.

Risks

• No specific risks related to Invivyd, Inc.'s operations or financial health are disclosed in this beneficial ownership report.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Invivyd, Inc.'s future performance or operations.

Industry Context

StockSavvy.ai notes that beneficial ownership filings like this Schedule 13G provide transparency into institutional investor positions, which can sometimes indicate broader sector interest or specific investment theses within the biotechnology or pharmaceutical industry, depending on Invivyd's primary focus.

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership, potentially influencing market perception of the stock's liquidity and investor base.

Key Dates

Keywords

Invivyd Inc, Soleus Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Ownership, Passive Investment, Biotechnology, Pharmaceuticals